期刊文献+

c-Ha-ras在转基因小鼠模型C57-ras各组织中的表达谱分析 被引量:6

Gene Expression Profile Analysis on Human c-Ha-ras Gene Expression in C57-ras Cancer Transgenic Mice
下载PDF
导出
摘要 目的:分析转基因c-Ha-ras在C57-ras癌症小鼠模型中的组织表达谱及时空表达差异。方法:利用半定量及荧光定量RT-PCR法,分析不同首建鼠系、不同周龄小鼠各脏器中转基因c-Ha-ras的表达。结果:转基因c-Ha-ras在心、肝等13种组织器官中均有表达,在肺脏中表达最高,在肝脏中表达最低,No.2、No.3和No.5等3个首建鼠均呈现相似的变化规律;转基因在No.5首建鼠中表达水平最高,而在同一个首建鼠系中,12周龄时表达高于8周龄和24周龄。结论:转基因c-Ha-ras在各脏器中能高效表达,并间接表明该转基因能稳定遗传,为C57-ras癌症小鼠模型用于新药临床前致癌性评价提了供理论支持。 Objective: To analyze gene expression profile and the time-space expression distribution of c-Ha-ras gene in C57-ras cancer transgenic mice. Methods:Primers were designed according to c-Ha-ras gene sequence, we analyzed expression profile in different founders and various tissues of C57-ras cancer transgenic mice by semi-quantitative RT-PCR and real-time RT-PCR method. Results:Analysis showed that c-Ha-ras had the high-est expressional level in lung, and lowest in liver. Similar change rule were found in No.2, No.3 and No.5 lines. In the aspect of expression in different time phase, comparison was done in the same line, 12-week C57-ras mice was higher than 8-week and 24-week. Among all the three founder lines, c-Ha-ras expressed highest in No.5. Conclusion:Transgenic c-Ha-ras expressed in the C57-ras cancer mice, which provided theoretical support for applying this mouse model in new drug preclinical carcinogenicity evaluation. Due to the highest expression in line No.5, it might be breeding and studied in carcinogenicity preferentially. Furthermore, since analysis was based on 12 generations of C57-ras mice, expression in various organs and different generations verified the stable hered-ity of c-Ha-ras gene.
出处 《生物技术通讯》 CAS 2013年第5期636-640,共5页 Letters in Biotechnology
关键词 C57-ras癌症小鼠模型 转基因c-Ha-ras 半定量PCR 荧光定量PCR 基因表达谱 C57-ras cancer transgenic mice transgene c-Ha-ras semi-quantitative RT-PCR real-time RT- PCR gene expression profile
  • 相关文献

参考文献20

  • 1Houdebine L M. The methods to generate transgenic animals and to control transgene expression[J]. Biotechnology, 2002,98 (2-3):145-160.
  • 2Eszterhas S K, Bouhassira E E, Martin D I K, et al. Tran- scriptional interference by independently regulated genes oc- curs in any relative arrange arrangement of the genes and is influenced by chromosomal integration position[J]. Mol Cell Bio, 2002,22(2):469-479.
  • 3Houdebine L M. Transgenie animal bioreaetors[J]. Transgenie Res, 2000,9(4):305-320.
  • 4Kouzarides T. Chromatin modifieations and their funetion[J]. Cell, 2007,128(4):693-705.
  • 5Whitelaw E, Sutherland H, Kearns M, et al. Epigenetic ef- fects on transgene expression[J]. Methods Mol Biol, 2001,158: 351-368.
  • 6Houdebine L M. The methods to generate transgenie animals and to control transgene expression. Bioteehnology, 2002,98 (2-3):145-160.
  • 7Wang Y, Song Y T, Liu Q, et al. Quantitative analysis of len-tiviral transgene expression in mice over seven generations. Transgenic Res, 2010,19(5):775-784.
  • 8International conference on harmonization. Guidance for indus- try S1B testing for carcinogenicity of pharmaceuticals(1997)[EB/ OL]. http:///www, fda. gov/cder/guidance/index.htm.
  • 9范昌发,岳秉飞,王军志,等.含有人源原癌基因c-Ha-ras的转基因小鼠的制作方法及其用途[P],中国专利,200810101666.0.2009-09-16.
  • 10周舒雅,左琴,刘娃苏,等.C57-ras转基因小鼠模型的建市[J].药物分析杂志(已接收).

二级参考文献6

  • 1萨姆布鲁克J 弗里奇EF.分子克隆实验指南(第二版)[M].北京:科学出版社,1992..
  • 2Liu M,Cancer Res,1998年,58卷,21期,4947页
  • 3Wang X J,Oncogene,1998年,17卷,1期,35页
  • 4金冬雁(译),分子克隆实验指南(第2版),1992年
  • 5Capon D J,Nature,1983年,302卷,33页
  • 6张贺,王承利,王洋.转基因动物研究进展[J].动物医学进展,2008,29(7):59-62. 被引量:9

共引文献12

同被引文献45

  • 1宋征,徐景宏,王庆利,马璟.转基因小鼠在药物致癌性评价中的应用[J].中国药理学与毒理学杂志,2010,24(6):557-561. 被引量:11
  • 2张俭,黄星群,刘建军.BALB/c小鼠繁殖性能的观察及分析[J].四川动物,2006,25(1):179-181. 被引量:7
  • 3吴清洪,顾为望,张嘉宁,袁进.SPF级C57BL/6J小鼠生长发育和繁殖性能指标的测定[J].中国比较医学杂志,2006,16(10):606-607. 被引量:15
  • 4王晓建,杨旭,宋晓东,张禅那,刘继斌,邸冉,张连峰,惠汝太.实时荧光定量PCR法检测转基因小鼠拷贝数[J].中国实验动物学报,2007,15(3):170-174. 被引量:27
  • 5Miyamoto S, Yasui Y, Kim M, el al. A novel rasH2 mous carcinogenesis model that is highly susceplible to) 4-NQO-in- duced tongue and esophageal carcinogenesis is useful for pre- clinical chemoprevention studies[JI. Carcinogenesis, 2008,29(2): 8-18-426.
  • 6Palazzi X, Kergozien-Framer/ S. Use of rasH2 transgenic mice for carcinogenesis testing of medical implants[J]. Exp Toxicol Pathol, 2009,61(5):433-441.
  • 7Cho W S, Jeong J, Choi M, et al. 26-Week carcinogenicity study of di-isodecyl phthalate by dietary administration to CB6FI-rasH2 transgenic mice[J]. Arch Toxicol, 2011,85(1):59- 66.
  • 8Paranjpo M G, Elbekaei R H, Shah S A, et al. Historical control data of spontaneous tumors in transgnnic CByB6F1-Tg (HRAS)2Jic(Tg.rasH2) mice[J]. Int J Toxicol, 2013,32(1):48-57.
  • 9Yamamoto S, Mitsumori K, Kodama Y, et al. Rapid induction of more malignant tumors by various genotoxic carcinogens in transgenic mice harboring a human prototype c-Ha-ras gene than in control non-transgenic mice[J]. Carcinogenesis, 1996. 17(11):2455-2461.
  • 10Yamamoto S, Urano K, Koizumi H, et aL Validation of trans- genie mice carrying the human prototype c-Ha-ms gene as a bioassay model for rapid carcinogenicity testing[J]. Environ Health Perspect, 1998,106(Suppl 1):57-69,.

引证文献6

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部